Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentered, Single-group Phase 2, Exploratory, Open-label Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in the Treatment of Adult Participants With IgAN

Next Previous
Search
Trial Profile

A Multicentered, Single-group Phase 2, Exploratory, Open-label Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in the Treatment of Adult Participants With IgAN

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sparsentan (Primary) ; Sodium-glucose transporter 2 inhibitors
  • Indications IgA nephropathy
  • Focus Therapeutic Use
  • Acronyms SPARTACUS
  • Sponsors Travere Therapeutics

    • Most Recent Events

    • 07 Nov 2024 Status changed from active, no longer recruiting to completed.
    • 26 Oct 2024 According to a Travere Therapeutics media release, data from this study were presented at the American Society of Nephrology (ASN).
    • 26 Oct 2024 Results presented in a Travere Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top